Anti-BCMA single domain antibodies and application thereof
A group of anti-BCMA single domain antibodies, as well as genes of the single domain antibodies in the group, a vector containing the single domain antibodies in the group, a chimeric antigen receptor, and a T cell modified by a chimeric antigen receptor, and detection and treatment application of the single domain antibodies in the group. The anti-BCMA single domain antibodies have high activity, high stability, high specificity, and high binding capability.
1. An anti-BCMA (B cell maturation antigen) single domain antibody, comprising framework regions and complementarity determining regions, wherein the complementarity determining regions comprise the amino acid sequences of CDR1, CDR2, and CDR3 in SEQ ID NO: 67.
2. The antibody of claim 1 , wherein the single domain antibody comprises an amino acid sequence of SEQ ID NO:67 or is an amino acid sequence of SEQ ID NO: 67.
3. A chimeric antigen receptor, comprising the single domain antibody of claim 1 .
4. The antibody of claim 1 , wherein said single domain antibody is a humanized antibody.
5. The chimeric antigen receptor of claim 3 , comprising more than one of the single domain antibody,
wherein the single domain antibodies are the same.
6. The chimeric antigen receptor of claim 3 , comprising more than one of the single domain antibody,
wherein the single domain antibodies are different.
7. A method of treating diseases associated with abnormal BCMA (B cell maturation antigen) expression, the method comprising:
administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising the single domain antibody of claim 1 .
8. The method of claim 7 , wherein said disease associated with abnormal BCMA expression is a multiple myeloma disease.
9. The method of claim 7 , wherein the single domain antibody can be used to detect BCMA.
10. The method of claim 7 , wherein said single domain antibody is able to block an interaction between BAFF (B cell-activating factor) and BCMA.
11. The method of claim 10 , wherein said single domain antibody is linked to one or more of cytotoxicity agent(s), enzyme phase(s), radioisotope(s), fluorescent compound(s) or chemiluminescent compound(s).